Decreased In Vitro Susceptibility to Zidovudine of HIV Isolates Obtained from Patients with AIDS
- 1 February 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 161 (2), 326-329
- https://doi.org/10.1093/infdis/161.2.326
Abstract
This study tested isolates of human immunodeficiency virus, obtained beforeand after zidovudine therapy from 10 patients, for susceptibility to the drug in vitro. The isolates collected after therapy were less susceptible to zidovudine as assessed by replication in MT-2 cells and production of reverse transcriptase activity by infected mononuclear leucocytes in the presence of the drug. Furthermore, pretherapy isolates were sensitive to a range of zidovudine concentrations when 100% inhibition was used as the end point. The loss of zidovudine susceptibility did not correlate with any clinical or virologic consequences in this small group of patients.Keywords
This publication has 4 references indexed in Scilit:
- Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex with a Regimen of 3′-Azido-2′,3′-Dideoxythymidine (Azidothymidine or Zidovudine) and AcyclovirAnnals of Internal Medicine, 1988
- ISOLATION OF HIV FROM AUSTRALIAN PATIENTS WITH AIDS, AIDS RELATED CONDITIONS AND HEALTHY ANTIBODY POSITIVE INDIVIDUALS*Australian and New Zealand Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985